群体药动学应用于个体化给药的研究进展

林艳

doi:10.3969/j.issn.1006-0111.2015.04.002

群体药动学应用于个体化给药的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.002

林艳

同济大学附属杨浦医院药剂科, 上海 200433

Research progress of population pharmacokinetics applying to individualized medication

LIN Yan

Department of Pharmacy, Yangpu Hospital affiliated to Tongji University, Shanghai 200433, China

摘要: 群体药动学运用经典的药动学原理结合统计学方法,以稀疏数据预测患者血药浓度,可达到监测药物体内过程和指导临床个性化给药的目的。查阅近年来的相关文献,结合实例综述群体药动学应用于治疗窗窄的药物、个体差异大的药物、联合用药、特殊人群用药等方面的最新进展,为其深入研究和指导临床用药提供参考。
- 群体药动学 /
- 个体化给药 /
- 非线性混合效应模型 /
- Bayesian反馈法
Abstract: Combining the classic pharmacokinetic principles and statistical methods, population pharmacokinetics (PPK) can predict individual pharmacokinetic parameters accurately with sparse data in patients, which may be used for monitoring drug concentration in patients and realizing individual dose regimen. In this article, we review the recent application of PPK in drugs with narrow therapeutic windows or great individual differences, combining medication, medication in special populations and so on, providing useful information for further investigation of PPK and its application in clinical medication.
- population pharmacokinetics /
- individual dose regimen /
- nonlinear mixed effect model /
- Bayesian forecasting

[1]	倪天庆, 胡思源, 司端运, 等. 中药儿童群体药动学试验设计要点[J]. 中草药, 2013, 44(021): 3089-3091.
[2]	张弨, 翟所迪. 群体药动学在治序药物监测中的应用[J]. 临床药物治疗杂志, 2006, 4(1): 45-50.
[3]	蒋新国.生物药剂学与药物动力学[M]. 北京: 高等教育出版社, 2009: 538-540.
[4]	Tatarinova T, Neely M, Bartroff J, et al.Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian[J].J Pharmacokinet Pharmacodyn, 2013, 40(2): 189-199.
[5]	Wakefield J, Walker S. Bayesian nonparametric population models: formulation and comparison with likelihood approaches[J].J Pharmacokinet Biopharm, 1997, 25(2): 235-253.
[6]	Rosner GL, Muller P. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models[J].J Pharmacokinet Biopharm, 1997, 25(2): 209-233.
[7]	林翠鸿, 王长连, 柯蒙. 群体药动学及其在个体化给药中的应用[J].中国临床药学杂志, 2005,14(01): 58-60.
[8]	Schaeftlein A, Minichmayr IK, Kloft C. Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data[J].Eur J Pharm Sci, 2014,57:68-73.
[9]	Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy[J].Ther Drug Monit, 2012, 34(4): 368-371.
[10]	胡敏, 张静华, 孙鹤, 等. 群体药动学原理及NONMEM法数据分析[J].药学服务与研究, 2002,2(4): 227-230.
[11]	Sherwin CM, Kiang TK, Spigarelli MG, et al. Fundamentals of population pharmacokinetic modelling: validation methods[J].Clin Pharmacokinet, 2012, 51(9): 573-590.
[12]	Krauss M, Burghaus R, Lippert JOR, et al. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification[J].In Silico Pharmacology, 2013, 1(1): 1-11.
[13]	Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J].Clin Pharmacokinet, 2004, 43(10): 623-653.
[14]	Golubovic B, Vucicevic K, Radivojevic D, et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients—population pharmacokinetic approach[J].Eur J Pharm Sci, 2013, 52: 34-40.
[15]	Seng KY, Hee KH, Soon GH, et al. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients[J].J Clin Pharmacol, 2014, 54(2):215-224.
[16]	Yamamoto M, Kuzuya T, Baba H, et al. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type[J].J Clin Pharm Ther, 2009, 34(4): 473-483.
[17]	翁芳娟. 万古霉素的群体药动学研究[J].海峡药学, 2013,25(7): 207-209.
[18]	N PP, D BBF. The epilepsy prescriber's guide to antiepileptic drugs[M].Oxford: Cambridge University Press, 2010.
[19]	Jovanovic M, Sokic D, Grabnar I, et al. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling[J].Eur J Pharm Sci, 2013, 50(3-4): 282-289.
[20]	Marsot A, Boulamery A, Bruguerolle B, et al. Population pharmacokinetic analysis during the first 2 years of life: an overview[J].Clin Pharmacokinet, 2012, 51(12): 787-798.
[21]	Udy AA, Covajes C, Taccone FS, et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?[J].Int J Antimicrob Agents, 2013, 41(6): 564-568.
[22]	Conil JM, Georges B, Fourcade O, et al. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration[J].Int J Clin Pharmacol Ther, 2007, 45(3): 133-142.
[23]	Conil JM, Georges B, Ravat F, et al. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations[J].Clin Ther, 2013, 35(10): 1603-1612.
[24]	柳晓泉, 陈渊成, 郝琨, 等. 药动学一药效学结合模型的研究进展及在新药研发中的应用[J].中国药科大学学报, 2007, 38(6): 481-488.
[25]	王清, 朱萱萱, 周杰, 等. 参麦注射液在心肌缺血患者体内的群体药动学研究[J].中华中医药学刊, 2013,31(12): 2702-2705.
[26]	Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the neoral formulation[J].Biodrugs, 2001, 15(5): 279-290.
[27]	Yoshida K, Kimura T, Hamada Y, et al. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from sandimmune to neoral in stable renal transplant patients[J].Transplant P, 2001, 33(7): 3146-3147.
[28]	Yue CS, Huynh HH, Raymond C, et al. Population pharmacokinetic and pharmacodynamic modeling of acetazolamide in peritoneal dialysis patients and healthy volunteers[J].J Pharm Pharm Sci, 2013, 16(1): 89-98.
[29]	Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil[J].J Clin Pharmacol, 2013, 53(1): 29-40.

[1]	陈灿昕, 缪竹威, 缪朝玉. 血小板特异性Metrnl基因敲除小鼠模型的构建与验证 . 药学实践与服务, 2025, 43(3): 117-123. doi: 10.12206/j.issn.2097-2024.202409031
[2]	何静, 安晔, 张朝绅. 复方黑参滴丸与复方黑参丸药效学实验比较研究 . 药学实践与服务, 2025, 43(1): 17-21. doi: 10.12206/j.issn.2097-2024.202404009
[3]	曹奇, 张嘉宝, 王培. 基于无监督自动降维分析与手动圈门联用的骨骼肌髓系细胞多色流式分析方法 . 药学实践与服务, 2025, 43(3): 118-122. doi: 10.12206/j.issn.2097-2024.202404077
[4]	段禹, 刘爱军. 活血化瘀法治疗血管性痴呆的研究进展 . 药学实践与服务, 2025, 43(4): 151-155, 173. doi: 10.12206/j.issn.2097-2024.202408045
[5]	徐尧, 马春辉, 李志勇. 高血压对心血管纤维化及sFRP2表达的影响 . 药学实践与服务, 2025, 43(4): 1-5. doi: 10.12206/j.issn.2097-2024.202409055
[6]	江冼芮, 段雅倩, 刘畅, 张成中. 淫羊藿中黄酮苷类化合物的群体感应抑制作用研究 . 药学实践与服务, 2025, 43(4): 1-5. doi: 10.12206/j.issn.2097-2024.202409060
[7]	姚小静, 计佩影, 陆峰, 施国荣, 傅翔. 表面增强拉曼光谱法快速测定尿液中曲马多的研究 . 药学实践与服务, 2025, 43(4): 185-189. doi: 10.12206/j.issn.2097-2024.202401072
[8]	肖农, 陆诗依, 唐文雅, 居敏俐, 徐刚锋, 杨明华. 中成药微生物计数法前处理的影响因素和优化方法 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202403014
[9]	晁亮, 王辉, 沈淑琦, 游飘雪, 冀凯宏, 洪战英. 基于UHPLC-Q/TOF-MS代谢组学策略的葛根-知母药对防治阿尔茨海默病的药效与作用机制研究 . 药学实践与服务, 2025, 43(1): 30-40. doi: 10.12206/j.issn.2097-2024.202409035
[10]	冯一帆, 严啸东, 张文彬, 李炳锋, 郭美丽. 菸花苷长期给药对脑缺血再灌注损伤大鼠神经功能的影响 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202407038
[11]	魏雨辰, 田家盛, 王道鑫, 凌期盛, 王治, 缪朝玉. 烟酰胺单核苷酸口服给药对高血压大鼠的影响 . 药学实践与服务, 2025, 43(5): 1-9. doi: 10.12206/j.issn.2097-2024.202412006
[12]	崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华. 肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2025, 43(1): 6-9, 21. doi: 10.12206/j.issn.2097-2024.202404006
[13]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[14]	王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉. 全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
[15]	邹思, 吴岩斌, 吴锦忠, 吴建国, 黄家兴. 虎奶菇菌核多糖功能化纳米硒抗疲劳功效研究 . 药学实践与服务, 2024, 42(10): 426-432. doi: 10.12206/j.issn.2097-2024.202206072
[16]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[17]	陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠. UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
[18]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[19]	凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋. 星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
[20]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062

点击查看大图

计量

文章访问数: 5710
HTML全文浏览量: 584
PDF下载量: 871
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

群体药动学应用于个体化给药的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.002

Research progress of population pharmacokinetics applying to individualized medication

计量

群体药动学应用于个体化给药的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.002

同济大学附属杨浦医院药剂科, 上海 200433

English Abstract

Research progress of population pharmacokinetics applying to individualized medication

Department of Pharmacy, Yangpu Hospital affiliated to Tongji University, Shanghai 200433, China

全文HTML

目录

全文HTML

留言板

群体药动学应用于个体化给药的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.002

Research progress of population pharmacokinetics applying to individualized medication

计量

出版历程

群体药动学应用于个体化给药的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.002

同济大学附属杨浦医院药剂科, 上海 200433

English Abstract

Research progress of population pharmacokinetics applying to individualized medication

Department of Pharmacy, Yangpu Hospital affiliated to Tongji University, Shanghai 200433, China

全文HTML

目录

全文HTML